Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of Torque Teno Virus DNA Load and Tacrolimus in Peripheral Blood Mononuclear Cells of Adult Kidney Transplant Patients.

Therapeutic drug monitoring·2026

Same author

Some observed problems of the evidence presented for zolmitriptan nasal spray in the "Evidence-Based Recommendations of Pharmacological Treatment of Migraine Attacks".

Cephalalgia : an international journal of headache·2025

Same author

Limited Sampling Strategies to Predict Mycophenolic Acid and Tacrolimus Area Under the Concentration-Time Curve in Steroid-Free Kidney Transplant Patients.

Basic & clinical pharmacology & toxicology·2025

Same author

Methodology of drug trials in migraine: History and suggestions for the future.

Cephalalgia : an international journal of headache·2024

Same author

Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney-transplanted patients.

British journal of clinical pharmacology·2024

Same author

Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users.

British journal of clinical pharmacology·2024

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Pharmacogenomics and migraine: possible implications.

Peer Tfelt-Hansen¹, Kim Brøsen

¹Danish Headache Centre, Department of Neurology, University of Copenhagen, Glostrup Hospital, Glostrup 2600, Denmark, tfelt@inet.uni2.dk

The Journal of Headache and Pain

|January 25, 2008

Summary

Pharmacogenomics, the study of genetic influences on drug response, offers personalized migraine treatment. Understanding genetic variability can optimize drug therapy for individual patients.

More Related Videos

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Related Experiment Videos

Last Updated: Jul 8, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies

Published on: November 1, 2024

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Area of Science:

Pharmacogenomics
Genetics
Pharmacology

Background:

Drug response is influenced by a complex interplay of genes, environment, and constitutional factors.
Genetic variability significantly impacts how individuals process and respond to medications.
Personalized medicine aims to tailor treatments based on individual biological differences.

Purpose of the Study:

To explore the implications of pharmacogenomics in the treatment of migraine.
To highlight the role of genetic variability in drug efficacy for migraine management.
To discuss the future integration of pharmacogenomics into therapeutic strategies.

Main Methods:

Review of current literature on pharmacogenomics and migraine treatment.
Analysis of genetic variability in pharmacokinetic and pharmacodynamic drug pathways.
Discussion of potential applications in acute and preventive migraine therapies.

Main Results:

Genetic variations can influence both how drugs are metabolized (pharmacokinetics) and their effects (pharmacodynamics).
This variability has direct implications for the effectiveness and safety of migraine medications.
Pharmacogenomic insights can guide the selection and dosing of migraine treatments.

Conclusions:

Pharmacogenomics provides a scientific foundation for optimizing drug therapy based on a patient's genetic makeup.
It is poised to become a crucial component of future migraine treatment strategies.
Personalized drug therapy informed by genetics promises improved patient outcomes.